Onconetix Equity

What does Onconetix do? Blue Water Biotech, Inc. generates revenue through the development and licensing of transformative vaccine candidates. The company focuses on a streptococcus pneumonia vaccine candidate targeting acute otitis media in children and pneumonia in the elderly, alongside a universal flu vaccine designed to protect against all virulent strains. It also licenses a norovirus S&P nanoparticle VLP platform from Cincinnati Children’s Hospital Medical Center to develop vaccines for diseases like Marburg and monkeypox. Collaborations with the University of Texas Health Science Center in San Antonio (UT Health) support the development of a Chlamydia vaccine candidate. The primary buyers of Blue Water Biotech's products are global health organizations and pharmaceutical companies seeking innovative vaccine solutions. The company's portfolio targets high-need segments including pediatric infectious diseases, elderly respiratory health, and emerging viral threats such as Marburg and monkeypox. Licensing agreements with institutions like Cincinnati Children’s Hospital Medical Center and UT Health provide key revenue streams through technology transfer and co-development partnerships. Blue Water Biotech's business model centers on R&D-driven innovation, with revenue derived from vaccine development milestones, licensing fees, and potential future sales of approved vaccines. The company's focus on addressing significant global health challenges through transformational therapies positions it to secure partnerships with healthcare institutions and pharmaceutical firms interested in expanding their vaccine portfolios. Onconetix is one of the most popular companies on Eulerpool.